BACKGROUND: We sought to examine the outcomes of second primary lung cancers in the large population-based Surveillance Epidemiology and End Results (SEER) database. We also sought to study the outcomes of synchronous second non-small-cell lung cancers (NSCLCs), classified as stage IVA (M1A) according to the seventh edition of the TNM staging for lung cancer. METHODS: Data of patients with at least two primary lung cancers were obtained. All available variables potentially associated with the incidence of a second primary lung cancer were examined. The overall survival of patients with synchronous NSCLC was compared with those with metachronous and stage IV NSCLC. RESULTS: A small proportion (1.5%) of patients with lung cancer developed a second primary. A second primary is associated with younger age, female gender, earlier stage, and white race. The median survival of patients with metachronous NSCLCs (n = 3352) was worse than those with synchronous NSCLCs (n = 1858) (median survival 22 mo versus 29 mo, respectively; P < 0.01). After adjusting for age, race, gender, stage, and histology of both primaries, this difference in survival between patients with synchronous and metachronous second primary lung cancers was not statistically significant, but was better than those with stage IV NSCLC (n = 127,654; median survival 4 mo). CONCLUSIONS: The incidence of second primary lung cancer is lower than that previously reported. Factors associated with good prognosis predict a second primary. Synchronous NSCLCs have an outcome better than a stage IV (M1a) designation. These patients should receive appropriate stage-specific multi-modality therapy suitable for the independent stage of each cancer without considering them unresectable. (c) 2010 Elsevier Inc. All rights reserved.
BACKGROUND: We sought to examine the outcomes of second primary lung cancers in the large population-based Surveillance Epidemiology and End Results (SEER) database. We also sought to study the outcomes of synchronous second non-small-cell lung cancers (NSCLCs), classified as stage IVA (M1A) according to the seventh edition of the TNM staging for lung cancer. METHODS: Data of patients with at least two primary lung cancers were obtained. All available variables potentially associated with the incidence of a second primary lung cancer were examined. The overall survival of patients with synchronous NSCLC was compared with those with metachronous and stage IV NSCLC. RESULTS: A small proportion (1.5%) of patients with lung cancer developed a second primary. A second primary is associated with younger age, female gender, earlier stage, and white race. The median survival of patients with metachronous NSCLCs (n = 3352) was worse than those with synchronous NSCLCs (n = 1858) (median survival 22 mo versus 29 mo, respectively; P < 0.01). After adjusting for age, race, gender, stage, and histology of both primaries, this difference in survival between patients with synchronous and metachronous second primary lung cancers was not statistically significant, but was better than those with stage IV NSCLC (n = 127,654; median survival 4 mo). CONCLUSIONS: The incidence of second primary lung cancer is lower than that previously reported. Factors associated with good prognosis predict a second primary. Synchronous NSCLCs have an outcome better than a stage IV (M1a) designation. These patients should receive appropriate stage-specific multi-modality therapy suitable for the independent stage of each cancer without considering them unresectable. (c) 2010 Elsevier Inc. All rights reserved.
Authors: Chip M Lynch; Behnaz Abdollahi; Joshua D Fuqua; Alexandra R de Carlo; James A Bartholomai; Rayeanne N Balgemann; Victor H van Berkel; Hermann B Frieboes Journal: Int J Med Inform Date: 2017-09-25 Impact factor: 4.046
Authors: Joe Y Chang; Yung-Hsien Liu; Zhengfei Zhu; James W Welsh; Daniel R Gomez; Ritsuko Komaki; Jack A Roth; Stephen G Swisher Journal: Cancer Date: 2013-06-24 Impact factor: 6.860
Authors: Konstantinos Leventakos; Tobias Peikert; David E Midthun; Julian R Molina; Shanda Blackmon; Francis C Nichols; Yolanda I Garces; Christopher L Hallemeier; Stephen J Murphy; George Vasmatzis; Sarah L Kratz; William P Holland; Charles F Thomas; John J Mullon; K Robert Shen; Stephen D Cassivi; Randolph S Marks; Marie Christine Aubry; Alex A Adjei; Ping Yang; Mark S Allen; Eric S Edell; Dennis Wigle; Aaron S Mansfield Journal: J Thorac Oncol Date: 2017-06-03 Impact factor: 15.609
Authors: Frances A Shepherd; Caroline Domerg; Pierre Hainaut; Pasi A Jänne; Jean-Pierre Pignon; Stephen Graziano; Jean-Yves Douillard; Elizabeth Brambilla; Thierry Le Chevalier; Lesley Seymour; Abderrahmane Bourredjem; Gwénaël Le Teuff; Robert Pirker; Martin Filipits; Rafael Rosell; Robert Kratzke; Bizhan Bandarchi; Xiaoli Ma; Marzia Capelletti; Jean-Charles Soria; Ming-Sound Tsao Journal: J Clin Oncol Date: 2013-04-29 Impact factor: 44.544
Authors: Mitchell D Ross; Sreeja Biswas Roy; Pradnya D Patil; Jasmine L Huang; Nitika Thawani; Ralph Drosten; Tanmay S Panchabhai Journal: Case Rep Pulmonol Date: 2018-02-20
Authors: Alexia Vogt; Sabine Schmid; Karl Heinimann; Harald Frick; Christian Herrmann; Thomas Cerny; Aurelius Omlin Journal: ESMO Open Date: 2017-05-02